Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


10.06.2024

3 Anticancer Res
2 BJU Int
2 BMC Cancer
1 Cancer
3 Cancer Res
1 Eur Radiol
3 Int J Radiat Oncol Biol Phys
3 Int J Urol
3 J Nucl Med
2 J Surg Oncol
2 Prostate
2 Urol Int
2 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Anticancer Res

  1. WAKITA N, Hara T, Suzuki K, Terakawa T, et al
    Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.
    Anticancer Res. 2024;44:2627-2635.
    PubMed         Abstract available

  2. WAIBEL S, Graf N, Storz J, Schultze-Seemann S, et al
    Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting the Prostate Specific Membrane Antigen.
    Anticancer Res. 2024;44:2343-2348.
    PubMed         Abstract available

  3. WANG YJ, Hao YY, Lee DH, Guo XY, et al
    Hispidin Increases Cell Apoptosis and Ferroptosis in Prostate Cancer Cells Through Phosphatidylinositol-3-Kinase and Mitogen-activated Protein Kinase Signaling Pathway.
    Anticancer Res. 2024;44:2533-2544.
    PubMed         Abstract available


    BJU Int

  4. HAHN AW, Manyam GC, Chapin BF, Zhang M, et al
    A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
    BJU Int. 2024 Jun 4. doi: 10.1111/bju.16414.
    PubMed         Abstract available

  5. BANCROFT EK, Page EC, Brook MN, Pope J, et al
    The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
    BJU Int. 2024 Jun 5. doi: 10.1111/bju.16432.
    PubMed         Abstract available


    BMC Cancer

  6. FU L, Zhang C, Wang Z, Tao W, et al
    Clinical application of serum tumor abnormal protein in prostate cancer patients.
    BMC Cancer. 2024;24:665.
    PubMed         Abstract available

  7. CHENG TS, Noor U, Watts E, Pollak M, et al
    Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.
    BMC Cancer. 2024;24:676.
    PubMed         Abstract available


    Cancer

  8. LABBAN M, Stone BV, Steele GL, Salinas KE, et al
    A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35366.
    PubMed         Abstract available


    Cancer Res

  9. BOUFAIED N, Chetta P, Hallal T, Cacciatore S, et al
    Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.
    Cancer Res. 2024;84:1834-1855.
    PubMed         Abstract available

  10. FRIGO DE
    Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment.
    Cancer Res. 2024;84:1742-1744.
    PubMed         Abstract available

  11. GALLAGHER K, Strobl MAR, Park DS, Spoendlin FC, et al
    Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy.
    Cancer Res. 2024;84:1929-1941.
    PubMed         Abstract available


    Eur Radiol

  12. NAKAI H, Suman G, Adamo DA, Navin PJ, et al
    Natural language processing pipeline to extract prostate cancer-related information from clinical notes.
    Eur Radiol. 2024 Jun 6. doi: 10.1007/s00330-024-10812.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  13. DYKSTRA M, Regan S, Yin H, McLaughlin P, et al
    Variation in Androgen Deprivation Therapy Use Among Men with Intermediate Risk Prostate Cancer: Results from a Statewide Radiation Oncology Quality Consortium.
    Int J Radiat Oncol Biol Phys. 2024 Jun 4:S0360-3016(24)00689.
    PubMed         Abstract available

  14. WESTERHOFF JM, Lalmahomed TA, Meijers L, Henke L, et al
    Patient reported outcomes following MR-guided radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2024 Jun 3:S0360-3016(24)00691.
    PubMed         Abstract available

  15. ALEXANDER GS, Krc RF, Assif JW, Sun K, et al
    Conditional Risk and Predictive Factors Associated with Late Toxicity for Prostate Cancer Patients Treated with External Beam Radiotherapy Alone on Randomized Trial RTOG 0126.
    Int J Radiat Oncol Biol Phys. 2024 May 31:S0360-3016(24)00686.
    PubMed         Abstract available


    Int J Urol

  16. KATO M, Shiota M, Kimura T, Hanazawa R, et al
    Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
    Int J Urol. 2024;31:662-669.
    PubMed         Abstract available

  17. HASHIMOTO K, Kosaka T, Terada N, Kimura T, et al
    Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023.
    Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15499.
    PubMed         Abstract available

  18. TANABE K, Kobayashi S, Tamiya T, Konishi T, et al
    Risk factors for the long-term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: A single-center, retrospective study of 306 patients.
    Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15507.
    PubMed         Abstract available


    J Nucl Med

  19. PHAM TT, Hungnes IN, Rivas C, Cleaver J, et al
    Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of (99m)Tc and (188)Re Theranostic Agents for Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.124.267450. doi: 10.2967/jnumed.124.267450.
    PubMed         Abstract available

  20. SEIFERT R, Telli T, Lapa C, Desaulniers M, et al
    Safety and Efficacy of Extended Therapy with [(177)Lu]Lu-PSMA: A German Multicenter Study.
    J Nucl Med. 2024;65:909-916.
    PubMed         Abstract available

  21. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
    A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
    PubMed         Abstract available


    J Surg Oncol

  22. CHEN HY, Liu JM, Shao IH, Liu KL, et al
    Modified three-layer vesicourethral reconstruction in robot-assisted radical prostatectomy can change cystography pattern and improve early recovery of continence.
    J Surg Oncol. 2024;129:1332-1340.
    PubMed         Abstract available

  23. BARLETTA F, Tappero S, Morra S, Incesu RB, et al
    Identifying low cancer-specific mortality risk lymph node-positive radical prostatectomy patients.
    J Surg Oncol. 2024;129:1305-1310.
    PubMed         Abstract available


    Prostate

  24. ABRAMOVIC I, Pezelj I, Dumbovic L, Skara Abramovic L, et al
    LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
    Prostate. 2024 Jun 2. doi: 10.1002/pros.24749.
    PubMed         Abstract available

  25. JASMINE S, Mandl A, Krueger TEG, Dalrymple SL, et al
    Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
    Prostate. 2024;84:909-921.
    PubMed         Abstract available


    Urol Int

  26. SIGG S, Arnold W, Grossmann NC, Baumeister P, et al
    Why Do Men Reject Adjuvant Radiotherapy following Radical Prostatectomy? A Systematic Survey.
    Urol Int. 2024;108:211-218.
    PubMed         Abstract available

  27. FARZAT M, Wagenlehner FM
    How Might the Number of Lymph Nodes Removed during RARP Impact the Postoperative Outcomes?
    Urol Int. 2024;108:175-182.
    PubMed         Abstract available


    Urology

  28. HOWLAND R, Srivastava A
    Editorial Comment on "Incidence and Management of Radiation Cystitis After Pelvic Radiotherapy for Prostate Cancer: Analysis from a National Database.".
    Urology. 2024 Jun 1:S0090-4295(24)00421-7. doi: 10.1016/j.urology.2024.
    PubMed        

  29. JIN T, An J, Wu W, Zhou F, et al
    Development and validation of a machine learning model for bone metastasis in prostate cancer: Based on inflammatory and nutritional indicators.
    Urology. 2024 May 31:S0090-4295(24)00415-1. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.